Dr. Kumar Discusses Study of Ixazomib in Multiple Myeloma

Shaji K. Kumar, MD
Published: Wednesday, Sep 06, 2017



Shaji K. Kumar, MD, professor of medicine, Mayo Clinic, discusses a study of ixazomib (Ninlaro) as maintenance therapy in multiple myeloma.

The current analysis focuses on the long-term outcomes of patients treated with ixazomib in combination with standard doses of lenalidomide (Revlimid) and dexamethasone, initial results of which were published 2 years ago.

The study enrolled 42 patients out of the 66 who did not go to a stem cell transplant but continued therapy with ixazomib, with a median follow-up of 55 months.
 
SELECTED
LANGUAGE


Shaji K. Kumar, MD, professor of medicine, Mayo Clinic, discusses a study of ixazomib (Ninlaro) as maintenance therapy in multiple myeloma.

The current analysis focuses on the long-term outcomes of patients treated with ixazomib in combination with standard doses of lenalidomide (Revlimid) and dexamethasone, initial results of which were published 2 years ago.

The study enrolled 42 patients out of the 66 who did not go to a stem cell transplant but continued therapy with ixazomib, with a median follow-up of 55 months.
 



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Addressing Post-Transplant Obstacles: Current and Emerging Strategies to Evolve the Standard of Care for Patients With Graft-Versus-Host DiseaseMar 28, 20192.0
2017 Year in Review™: Clinical Impact of Immunotherapies in the Treatment of CancerMar 30, 20191.75
Publication Bottom Border
Border Publication
x